Base de dados : LILACS
Pesquisa : D26 [Categoria DeCS]
Referências encontradas : 2904 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 291 ir para página                         

  1 / 2904 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1289244
Autor: Herrera Escandón, Álvaro; Sánchez Solanilla, Luis Fernando; Ramírez-Penuela, José Alejandro; Buitrago Sandoval, Andrés Felipe.
Título: Caracterización clínica y demográfica de pacientes adultos sometidos a valoración de la presión arterial con monitorización ambulatoria de la presión arterial. Registro EPEDMAPA / Clinical and demographic profile of adult patients subjected to an assessment of arterial hypertension with an ambulatory blood pressure monitoring device. EPEDMAPA Registry
Fonte: Rev. colomb. cardiol;27(5):368-372, sep.-oct. 2020. tab, graf.
Idioma: es.
Resumo: Resumen Introducción: la hipertensión arterial es un problema de salud pública que aumenta la mortalidad en todos los escenarios clínicos, pero es, además, el principal factor de riesgo modificable. Es una enfermedad altamente prevalente; cerca de un cuarto de la población del mundo la padece. Pocos pacientes la conocen y pocos están tratados de manera óptima. Objetivo: evaluar las características de pacientes a quienes se les realizó una monitorización ambulatoria de la presión arterial en un Hospital Universitario, con miras a describir el perfil clínico y demográfico. Métodos: estudio descriptivo retrospectivo, llevado a cabo en pacientes sometidos a monitorización ambulatoria de la presión arterial de 24 horas durante los meses de octubre y noviembre de 2015. Resultados: se confirmó hipertensión (de reciente diagnóstico o conocida) en el 75% de los estudios realizados. Se descartó hipertensión arterial en el 31% de los pacientes previamente clasificados como hipertensos. El 61% de los pacientes que se encontraban bajo tratamiento estaban bien controlados, la mayoría de ellos con un solo medicamento, principalmente antagonistas del receptor de angiotensina II. El patrón circadiano más prevalente en esta cohorte de pacientes fue el dipper (48%) seguido por el patrón de non-dipper (29%). Conclusiones: el monitorización ambulatoria de la presión arterial permite evaluar con exactitud el estado de la presión arterial de los pacientes con sospecha de hipertensión arterial. Esto aclara si los pacientes son realmente normotensos o hipertensos y discrimina las condiciones de la bata blanca y la hipertensión enmascarada, con lo cual se evitan tratamientos innecesarios y se favorece un mejor control de la presión arterial.

Abstract Introduction: Arterial hypertension is a public health problem that increases mortality in all clinical situations. It is also the main modifiable risk factor. It is a highly prevalent condition that is suffered by around 25% of the world population. Few patients are aware of it, and few receive the optimum treatment. Objective: To evaluate the characteristics of the patients on whom ambulatory blood pressure monitoring was carried out in a University Hospital, with a view to describing the clinical and demographic profile. Methods: A descriptive retrospective study was conducted on patients subjected to 24-hour ambulatory blood pressure monitoring, during the months of October and December 2015. Results: Hypertension (recently diagnosed or known) was confirmed in 75% of the studies performed. Arterial hypertension was ruled out in 31% of the patients previously classified as hypertensive. Of the patients that were receiving treatment, 61% were well-controlled, with the majority of them with a single drug, mainly an angiotensin II receptor agonist. The dipper was most prevalent circadian pattern, with 48%, followed by the non-dipper pattern in 29%. Conclusions: Ambulatory blood pressure monitoring helps in the evaluation of the blood pressure status accurately in patients with a suspicion of arterial hypertension. This clarifies whether the patients are really normotensive or hypertensive and discriminates between the "white coat" and masked hypertension conditions. This avoids unnecessary treatments and favours a better control of the blood pressure.
Descritores: Monitorização Ambulatorial da Pressão Arterial
Hipertensão
-Receptores de Angiotensina
Preparações Farmacêuticas
Estudos Retrospectivos
Diretório
Diagnóstico
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: CO369.9 - SCC - Sociedad Colombiana de Cardiologia y Cirugía Cardiovascular


  2 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1289249
Autor: Herruzo-Rojas, Manuel S; Martín-Toro, Miriam A; Carrillo-Bailén, Magdalena.
Título: Ranolazina en cardiopatía isquémica crónica: un factor protector frente a la fibrilación auricular de novo / Ranolazine in chronic ischaemic heart disease: a protective factor against de novo atrial fibrillation
Fonte: Rev. colomb. cardiol;27(5):400-404, sep.-oct. 2020. tab.
Idioma: es.
Resumo: Resumen Introducción: en pacientes con cardiopatía isquémica crónica, ranolazina se ha mostrado eficaz ante casos de angina. Estudios recientes la valoran como fármaco para prevenir la fibrilación auricular poscardioversión eléctrica, posquirúrgica o posinfarto. Objetivos: valorar la presencia a largo plazo de episodios de fibrilación auricular de novo en pacientes con cardiopatía isquémica crónica y nuevo episodio de angina inestable que inician ranolazina 350 o 500 mg/12 h, en comparación con el tratamiento habitual. Métodos: estudio observacional retrospectivo que compara la incidencia de fibrilación auricular de novo en 77 pacientes consecutivos, con diagnóstico de cardiopatía isquémica no revascularizable y nuevo ingreso por síndrome coronario agudo durante el año 2013, en comparación con los que iniciaron ranolazina frente a tratamiento convencional, en los 12 meses siguientes al evento. La detección de fibrilación auricular se basó en su presencia en un primer registro electrocardiográfico. Resultados: de 77 pacientes, 38 iniciaron ranolazina, sin diferencias en cuanto a las características basales de las dos poblaciones, con similares tasas de factores de riesgo cardiovascular clásicos, datos ecocardiográficos como tamaño auricular, o tratamiento previo empleado. Se observó una tasa de fibrilación auricular de novo del 5,3% en los pacientes tratados con ranolazina, frente al 23,1% en el grupo sin ranolazina (p<0,001). Al analizar el subgrupo de pacientes que presentó fibrilación auricular en su seguimiento, únicamente es significativa la no toma de ranolazina (p<0,001). Conclusión: el uso de ranolazina en pacientes con cardiopatía isquémica crónica no revascularizable podría suponer un efecto protector para el desarrollo de fibrilación auricular durante un seguimiento de al menos doce meses.

Abstract Introduction: Ranolazine has shown to be effective in cases of angina in patients with chronic ischaemic heart disease. Recent studies have evaluated it as a drug to prevent electrical post-cardioversion, post-surgical or post-infarction atrial fibrillation. Objectives: To perform a long-term evaluation of de novo atrial fibrillation episodes in patients with chronic ischaemic heart disease and a new episode of unstable angina that are taking 350 or 500 mg/12 h of ranolazine, in comparison with usual treatment. Methods: An observational, retrospective study was performed to compare the incidence of de novo atrial fibrillation in 77 consecutive patients with a diagnosis of non-revascularisable ischaemic heart disease and a new hospital admission due to acute coronary syndrome during the year 2013. These were compared with those that started with ranolazine and those on conventional treatment in the 12 months following the event. The detection of atrial fibrillation was based on its presence in a first electrocardiographic register. Results: Of the 77 patients, 38 were started on ranolazine, with no differences as regards the baseline characteristics of the two populations. They had similar rates of classic cardiovascular risk factors, echocardiographic data, such as atrial size, or previous treatment employed. A de novo atrial fibrillation rate of 5.3% was observed in the patients treated with ranolazine, compared to 23.1% in the non-ranolazine group (P<.001). On analysing the sub-group of patients that had an atrial fibrillation in their follow-up, only not taking of ranolazine was significant (P<.001). Conclusion: The use of ranolazine in patients with non-revascularisable ischaemic heart disease could have a protective effect against the development of atrial fibrillation during a 12 months follow-up.
Descritores: Fibrilação Atrial
Isquemia Miocárdica
Ranolazina
-Terapêutica
Preparações Farmacêuticas
Síndrome Coronariana Aguda
Fatores de Risco de Doenças Cardíacas
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Estudo Observacional
Responsável: CO369.9 - SCC - Sociedad Colombiana de Cardiologia y Cirugía Cardiovascular


  3 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1142615
Autor: Cruz, Alex Júnio Silva da; Santos, Jacqueline Silva; Pereira Júnior, Edmilson Antônio; Ruas, Cristina Mariano; Matos, Flávio de Freitas; Castilho, Lia Silva de; Abreu, Mauro Henrique Nogueira Guimarães.
Título: Prescriptions of analgesics and anti-inflammatory drugs in municipalities from a Brazilian Southeast state
Fonte: Braz. oral res. (Online);35:e011, 2021. tab, graf.
Idioma: en.
Projeto: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Resumo: Abstract The objective of this study was to describe dental prescriptions of non-steroidal anti-inflammatory drugs (NSAID), opioids, and analgesics dispensed by the Brazilian National Health System (BNHS, SUS in Portuguese) of a Southeastern state from January to December 2017, and to analyze their association with socioeconomic and oral health care services' characteristics at municipal level. Data were collected from the Brazilian Integrated Pharmaceutical Care Management System. Medicines were grouped according to the Anatomical Therapeutic Chemical Classification System. The total number of Defined Daily Doses (DDD) and DDD per 1,000 inhabitants (inhab.) per year were presented and compared between groups of municipalities. Data analysis used the Classification and Regression Tree model performed with IBM SPSS 25.0. The total number of NSAID, opioids, and analgesics prescriptions was 70,747 and accounted for 354,221.13 DDD. The most frequently prescribed medicine was ibuprofen (n = 24,676; 34.88%). The number of dental practitioners in the BNHS per 1,000 inhab. (p < 0.001), first dental appointment coverage (p = 0.010), oral health teams per 1,000 inhab. (p=0.022), and the proportion of rural population (p = 0.014) were variables positively associated with the number of DDD of NSAID per 1,000 inhab. per year. Bolsa Família program coverage per 1,000 inhab. (p = 0.022) was negatively associated with NSAID prescription. Regarding analgesics, first dental appointment coverage (p=0.002) and Bolsa Família program coverage per 1,000 inhab. (p = 0.012) were positively associated with DDD per 1,000 inhab. per year. In conclusion, dental prescriptions of analgesics and NSAID in the BNHS were associated with socioeconomic and oral health care services' characteristics.
Descritores: Prescrições de Medicamentos
Odontólogos
-Brasil
Preparações Farmacêuticas
Anti-Inflamatórios não Esteroides/uso terapêutico
Cidades
Papel Profissional
Analgésicos/uso terapêutico
Analgésicos Opioides/uso terapêutico
Limites: Humanos
Responsável: BR1.1 - BIREME


  4 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975093
Autor: Castro, Jaqueline Cristina da Silveira Xavier e; Botelho, Stephanie Ferreira; Machado, Taisa Roberta Lopes; Martins, Maria Auxiliadora Parreiras; Vieira, Liliana Batista; Reis, Adriano Max Moreira.
Título: Suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups / Adequação às faixas etárias pediátricas de medicamentos novos registrados no Brasil de 2003 a 2013
Fonte: Einstein (Säo Paulo);16(4):eAO4354, 2018. tab, graf.
Idioma: en.
Projeto: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Resumo: ABSTRACT Objective To analyze suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups. Methods A descriptive study of drugs with pediatric indication included in a retrospective cohort of new drugs registered in Brazil. The evaluation of drug suitability for the pediatric age group was performed using the following criteria: suitability of dosage form and capacity to deliver the recommended dose. The drugs were considered adequate for the pediatric age groups when they met both criteria. The statistical analysis included calculation of frequencies and proportions. Results Suitability due to the drug capacity to deliver the recommended dose was greater than 80% across all age groups. Regarding suitability of the dosage form, we identified that the older the age group, the greater suitability for pediatric use. Concerning the drugs presented in solid dosage form, we showed that half were classified as inadequate for one or more pediatric age groups to whom they were indicated. The adequacy of drugs to the pediatric age group was 64.3% for preschool children, 66.7% for full-term newborns, 66.7% for premature newborns, and over 70% for other age groups. Conclusion Drugs for children aged under 6 years were less often adequate, considering the dosage form and capacity to provide the recommended dose. The availability and proportional suitability of medicines for pediatric use are greater for older age groups, according to age groups the drug is registered for.

RESUMO Objetivo Analisar a adequação às faixas etárias pediátricas dos medicamentos novos registrados no Brasil no período de 2003 a 2013. Métodos Estudo descritivo dos medicamentos com indicação pediátrica incluídos em uma coorte retrospectiva de medicamentos novos registrados no Brasil. A avaliação da adequação do medicamento à faixa etária pediátrica foi realizada empregando os seguintes critérios: adequação da forma farmacêutica e capacidade de fornecer a dose recomendada. Os medicamentos foram considerados adequados às faixas etárias pediátricas quando preencheram os dois critérios. A análise estatística compreendeu cálculo de frequências e proporções. Resultados A adequação devido à capacidade do medicamento fornecer a dose recomendada foi superior a 80% em todas as faixas etárias. Em relação à adequação da forma farmacêutica, identificou-se que quanto maior a faixa etária, maior a proporção de adequação para uso pediátrico. Em relação aos medicamentos que se apresentavam em formas farmacêuticas sólidas, evidenciou-se que metade foi classificada como inadequada para uma ou mais faixas etárias pediátricas para as quais estavam indicados. A adequação dos medicamentos à faixa etária pediátrica foi 64,3% para pré-escolares, 66,7% para recém-nascidos a termo, 66,7% para recém-nascidos prematuros e superior a 70% para as demais faixas etárias. Conclusão Os medicamentos destinados às crianças menores de 6 anos apresentaram menor frequência de adequação, considerando a forma farmacêutica e a capacidade de fornecer a dose recomendada. A disponibilidade e a proporção de adequação dos medicamentos para uso pediátrico aumentam com a elevação da faixa etária para a qual o medicamento é registrado.
Descritores: Prescrições de Medicamentos/normas
Preparações Farmacêuticas/administração & dosagem
Cálculos da Dosagem de Medicamento
Uso Off-Label/normas
-Prescrições de Medicamentos/estatística & dados numéricos
Padrões de Referência
Brasil
Estudos Retrospectivos
Uso Off-Label/estatística & dados numéricos
Limites: Humanos
Recém-Nascido
Lactente
Pré-Escolar
Criança
Responsável: BR1.1 - BIREME


  5 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1249169
Autor: Raskovic, Aleksandar Lazar; Kvrgic, Maja Petar; Tomas, Ana Drago; Stilinovic, Nebojsa Petar; Cabarkapa, Velibor Spasoje; Stojsic-Milosavljevic, Anastazija Ðurica; Kusturica, Milica Nada Paut; Rakic, Dusica Branko.
Título: Antinociceptive activity of Thyme (Thymus vulgaris L. ) and interactions with neurotropics and analgesics
Fonte: Braz. J. Pharm. Sci. (Online);56:e18819, 2020. tab, graf.
Idioma: en.
Projeto: Provincial Secretariat for Science and Technological Development, Autonomous Province of Vojvodina; . Ministry of Science and Technological Development, Republic of Serbia; . MEDLEM.
Resumo: The plant world represents an important source of potential therapeutic agents, but concomitant administration of herbal and conventional medications may result in interactions with subsequent beneficial or adverse effects. This study was designed to examine the analgesic effect of thyme tincture and thyme syrup, two commonly used thyme formulations, and their interactions with codeine, paracetamol, pentobarbital and diazepam in mice. The identification and quantification of thymol and carvacrol were carried out by GC/MS and GC/FID. The analgesic activity was studied using a hot plate method. Effects of thyme syrup on diazepam-induced motor coordination impairment in rotarod test and on pentobarbital-induced sleeping time were also determined. Thymol (175.3 µg/mL and 9.73 µg/mL) and carvacrol (10.54 µg/mL and 0.55 µg/mL) concentrations were measured in tincture and syrup, respectively. Thyme syrup and tincture exhibited effective analgesic activity in the hot plate pain model. Pretreatment with thyme formulations reduced analgesic activity of codeine, and potentiated the analgesic activity of paracetamol. Co-administration of thyme formulations has led to potentiation of diazepam and pentobarbital depressive central nervous system effects. Thyme formulations interacted with tested conventional drugs, probably through interference with their metabolic pathways and succeeding altered concentrations and pharmacological effects.
Descritores: Thymus (Planta)/efeitos dos fármacos
Interações Medicamentosas
Analgésicos/efeitos adversos
-Pentobarbital/efeitos adversos
Preparações Farmacêuticas
Diazepam/efeitos adversos
Medicamentos Fitoterápicos
Limites: Animais
Masculino
Feminino
Camundongos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  6 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1156961
Autor: Department of PsychiatryBecker, Paula; Department of PsychiatryRazzouk, Denise.
Título: Direct healthcare costs and their relationships with age at start of drug use and current pattern of use: a cross-sectional study
Fonte: Säo Paulo med. j;139(1):18-29, Jan.-Feb. 2021. tab.
Idioma: en.
Resumo: ABSTRACT BACKGROUND: It is well known that early start of drug use can lead users to psychosocial problems in adulthood, but its relationship with users' direct healthcare costs has not been well established OBJECTIVES: To estimate the direct healthcare costs of drug dependency treated at a community mental health service, and to ascertain whether early start of drug use and current drug use pattern may exert influences on these costs. DESIGN AND SETTING: Retrospective cross-sectional study conducted at a community mental health service in a municipality in the state of São Paulo, Brazil. METHODS: The relationships between direct healthcare costs from the perspective of the public healthcare system, age at start of drug use and drug use pattern were investigated in a sample of 105 individuals. A gamma-distribution generalized linear model was used to identify the cost drivers of direct costs. RESULTS: The mean monthly direct healthcare costs per capita for early-start drug users in 2020 were 1,181.31 Brazilian reais (BRL) (274.72 United State dollars (USD) according to purchasing power parity (PPP)) and 1,355.78 BRL (315.29 USD PPP) for late-start users. Early start of drug use predicted greater severity of cannabis use and use of multiple drugs. The highest direct costs were due to drug dependence combined with alcohol abuse, and due to late start of drug use. CONCLUSIONS: Preventive measures should be prioritized in public policies, in terms of strengthening protective factors before an early start of drug use.
Descritores: Preparações Farmacêuticas
Transtornos Relacionados ao Uso de Substâncias
-Brasil
Estudos Transversais
Estudos Retrospectivos
Custos de Cuidados de Saúde
Atenção à Saúde
Limites: Humanos
Adulto
Responsável: BR1.1 - BIREME


  7 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1283652
Autor: Zhi, Kaining; Lebo, David B.
Título: A preformulation strategy for the selection of controlled-release components to simulate a subcutaneous implant / Una estrategia de preformulación para la selección de componentes de liberación controlada para simular un implante subcutáneo
Fonte: Bol. latinoam. Caribe plantas med. aromát;19(4):344-356, 2020. tab, ilus.
Idioma: en.
Resumo: Many chronic diseases require repetitive injections as maintenance treatment. It is therefore important to investigate a possible alternative. A simulated subcutaneous implant prototype was fabricated as a polymer matrix covered by cylinder-shape tubing having a porous membrane. Sucrose, bovine serum albumin, and gelatin were selected as matrix excipients. Eight APIs with different physiochemical properties were used to investigate the releasing mechanism. Drug release was tested through an in vitrodissolution apparatus. Drug release of eight APIs followed zero-order kinetics with a minimum 12-hour duration. Release rates also showed linear correlations with the APIs' solubilities under physiological pH. For releasing mechanism studies, different combinations of matrix and membrane were investigated in detail. A 144-hour continuous zero-order release of caffeine was achieved as the best controlled simulated prototype. The results showed that drug release of our simulated prototype was primarily achieved by drug diffusion rather than dissolution.

Muchas enfermedades crónicas requieren inyecciones repetitivas como tratamiento de mantenimiento. Por lo tanto, es importante investigar una posible alternativa. Se fabricó un prototipo de implante subcutáneo simulado a partir de una matriz de polímero cubierta por un tubo en forma de cilindro que tiene una membrana porosa. La sacarosa, la albúmina de suero bovino y la gelatina se seleccionaron como excipientes matriciales. Se utilizaron ocho APIs con diferentes propiedades fisicoquímicas para investigar el mecanismo de liberación. La liberación del fármaco se probó a través de un aparato de disolución in vitro. La liberación del fármaco de las ocho APIs siguió una cinética de orden cero con una duración mínima de 12 horas. Las tasas de liberación también mostraron correlaciones lineales con las solubilidades de las APIs a pH fisiológico. Para los estudios de mecanismos de liberación, se investigaron en detalle diferentes combinaciones de matriz y membrana. El prototipo simulado con mejor control logró una liberación continua de cafeína de orden cero durante 144 horas. Los resultados mostraron que la liberación del fármaco del prototipo simulado ocurrió principalmente mediante la difusión del fármaco en lugar de la disolución.
Descritores: Preparações Farmacêuticas/administração & dosagem
Implantes de Medicamento/metabolismo
-Técnicas In Vitro
Projetos Piloto
Simulação
Cromatografia Líquida de Alta Pressão
Tela Subcutânea
Preparações de Ação Retardada
Avaliação Pré-Clínica de Medicamentos
Liberação Controlada de Fármacos
Liofilização
Responsável: CL1.1 - Biblioteca Central


  8 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1249170
Autor: Departamento de Farmácia SocialDrummond, Paula Lana de Miranda; Divisão de Assuntos RegulatóriosSantos, Roberta Márcia Marques dos; Divisão de Assuntos RegulatóriosSilva, Cristine de Araújo; Departamento de Farmácia SocialPádua, Cristiane Aparecida Menezes de.
Título: Pharmacovigilance of thalidomide in the Brazilian Health System and patient safety
Fonte: Braz. J. Pharm. Sci. (Online);56:e18726, 2020. tab, graf.
Idioma: en.
Resumo: In Brazil, thalidomide is manufactured by a public laboratory, distributed by the Unified Health System (SUS), and regulated by the National Health Surveillance Agency (Anvisa). Despite the concerns regarding the adverse effects of thalidomide, few drug utilization studies have been conducted to describe processes and outcomes related to this drug. The aim of this study was to elucidate the issues related to the utilization and control of thalidomide, and patient safety within the scope of SUS. In this cross-sectional study, we evaluated the articulation between an outpatient dermatology service of a referral hospital in infectology, the manufacturer, and Anvisa. Four data sources were used: i) interviews with health professionals; ii) data from the Customer Service of the manufacturer, iii) data on adverse events reported to Anvisa, and iv) adverse events identified in outpatient service. Most health professionals interviewed knew the major thalidomide-related adverse effects. None of them ever reported adverse events to Anvisa or contacted the Customer Service. For over three years, there were 330 calls concerning thalidomide at Customer Service, 7% of which were related to adverse events. During a period of six years, Anvisa was notified of only 15 adverse events. Health professionals were aware of the adverse events associated with thalidomide, but not the necessity to report them. The low number of notifications recorded by Anvisa and the information obtained from Customer Service show that pharmacovigilance remains incipient. A pharmacovigilance system that integrates all the services associated with thalidomide is required to strengthen this activity within the SUS to improve patient safety.
Descritores: Pacientes Ambulatoriais/classificação
Talidomida/análise
Sistema Único de Saúde/classificação
Vigilância Sanitária/organização & administração
Agência Nacional de Vigilância Sanitária
Farmacovigilância
Segurança do Paciente/normas
-Preparações Farmacêuticas/administração & dosagem
Saúde/normas
Relatório de Pesquisa
Limites: Humanos
Masculino
Feminino
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  9 / 2904 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1290235
Autor: de Oliveira, Henrique Souza Barros.
Título: Does use of nonsteroidal anti-inflammatory drugs increase patients' clinical severity of COVID-19?
Fonte: Säo Paulo med. j;139(4):418-419, Jul.-Aug. 2021.
Idioma: en.
Descritores: Preparações Farmacêuticas
COVID-19
-Anti-Inflamatórios não Esteroides/efeitos adversos
SARS-CoV-2
Limites: Humanos
Tipo de Publ: Carta
Responsável: BR1.1 - BIREME


  10 / 2904 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-682351
Autor: Torres Pradilla, Mauricio; Olmos Olmos, Edgar.
Título: Reacciones medicamentosas severas Síndrome Stevens Johnson y síndrome DRESS / Severe drug reactions Stevens Johnson syndrome and DRESS syndrome
Fonte: Acta méd. colomb;38(2):76-82, abr.-jun. 2013. ilus, tab.
Idioma: es.
Resumo: Propósito: revisar y actualizar el síndrome de Steven-Johnson y el síndrome DRESS, que a pesar de no ser las reacciones medicamentosas más frecuentes, sí constituyen las más severas. Fuente de datos: Realizamos una revisión sistemática de la literatura médica, expuesta en las bases de datos: Pubmed, Medline y Cochrane. Selección de estudios: limitamos la búsqueda a artículos de revisión de literatura, guías de manejo y metaanálisis, publicados en inglés y español, sin límite en edad o sexo, utilizando términos MESH: Stevens-Johnson syndrome, DRESS syndrome. Los acoplamos a términos como assessment, associations, update y review. Extracción de datos y resultados: realizamos una lectura inicial de 338 trabajos, encontrando que varios de las referencias eran citadas en otros trabajos, por lo que seleccionamos 10 artículos y con base en estos realizamos la lectura crítica, clasificación y ordenamiento, para luego proceder a la redacción del texto. Conclusiones: hemos revisado dos importantes reacciones medicamentosas, entidades con un espectro clínico y etiopatogénico muy distinto, y numerosas asociaciones medicamentosas, sobre las que no existen realmente concensos globales de tratamiento, pero en la que todos los autores revisados coinciden en la suspensión de los medicamentos, como primera línea de tratamiento.

Purpose: to review and update the Stevens-Johnson syndrome and DRESS syndrome, which despite not being the most frequent drug reactions, are the most severe ones. Data sources: we conducted a systematic review of the medical literature, as described in the databases: PubMed, Medline and Cochrane. Study selection: we limited the search to articles of literature review, management guidelines and meta-analysis published in English and Spanish, with no limit on age or sex, using MESH terms: Stevens-Johnson syndrome, DRESS syndrome. We linked them to terms such as assessment, associations, update and review. Data extraction and results: we performed an initial reading of 338 studies, finding that several of the references were cited in other works, so we selected 10 articles and based on this we performed the critical reading, sorting and ordering, and then proceeded to the text drafting. Conclusions: we reviewed two important drug reactions, clinical entities with very different clinical and etiopathogenic spectrum and numerous drug combinations on which there is not a global treatment concensus, but in which all authors agree in the drug suspension as the frst line of treatment.
Descritores: Síndrome de Stevens-Johnson
Síndrome de Hipersensibilidade a Medicamentos
-Anormalidades Induzidas por Medicamentos
Preparações Farmacêuticas
Combinação de Medicamentos
Literatura
Tipo de Publ: Revisão
Responsável: CO70 - Asociación Colombiana de Medicina Interna



página 1 de 291 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde